CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 312 enrolled
Drug / intervention
Dulaglutide Pen +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03724981
NCT03724981Phase 4Completed
CompareCT.gov

Crossover Study Comparing the Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen

Eli Lilly and Company·interventional·Posted Oct 30, 2018·Updated Apr 24, 2020

In Brief

A Phase 4 clinical trial evaluating Dulaglutide Pen and Semaglutide Pen for Diabetes Mellitus, Type 2. Completed, enrolled 312 participants across 14 sites.

Detailed Summary

In this study participants will try out two different types of drug injection pens (dulaglutide and semaglutide) on a practice pad and decide which device they prefer. No study drug will be administered.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedOct 30, 2018
Enrollment StartOct 18, 2018
Primary CompletionApr 12, 2019
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 7.7 years ago

Interventions

Dulaglutide Pendrug

Injected on a practice pad.

Semaglutide Pendrug

Injected on a practice pad.